Table 2.
Site of infection and fungus family in patients with SARS-CoV-2 infection, comparing comparing fungal infection (FI) and non-fungal infection (NFI) groups.
| NFI | FI | p value | |
|---|---|---|---|
| Site infection | |||
| Respiratory | 349,611 (86.34%) | 5647 (97.43%) | < 0.001 |
| Genitourinary | 19,944 (4.93%) | 2324 (40.1%) | < 0.001 |
| Digestive | 2216 (0.55%) | 218 (3.76%) | < 0.001 |
| Circulatory | 470 (0.12%) | 23 (0.40%) | < 0.001 |
| Nervous | 68 (0.02%) | 5 (0.09%) | 0.001 |
| Fungus family | |||
| Mucocutaneous candidiasis | 0 (0.00) | 2588 (44.65%) | < 0.001 |
| Aspergillosis | 0 (0.00) | 1270 (21.91%) | < 0.001 |
| Invasive candidiasis | 0 (0.00) | 1081 (18.65%) | < 0.001 |
| Unspecified candidiasis | 0 (0.00) | 1038 (17.91%) | < 0.001 |
| Candidiasis of the skin | 0 (0.00) | 259 (4.47%) | < 0.001 |
| Unspecified mycosis | 0 (0.00) | 90 (1.55%) | < 0.001 |
| Dermatophytosis | 0 (0.00) | 19 (0.33%) | < 0.001 |
| Zygomycosis | 0 (0.00) | 5 (0.09%) | < 0.001 |
| Cryptococcosis | 0 (0.00) | 1 (0.02%) | < 0.001 |
| Resistance to antifungals | 0 (0.00) | 4 (0.07%) | < 0.001 |
Values are expressed as absolute number (percentage) and mean (standard deviation).